InvestSMART

Orthocell Limited (ASX: OCC) - Announcements

Current share price for OCC : $0.670 0.025 (3.88%)+

ASX company news and announcements for Orthocell Limited (OCC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Orthocell Limited (OCC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Orthocell Limited (OCC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Orthocell Limited (OCC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$183 Appendix 4G 29 Aug 2025 12:31PM $1.215 $0.670 fallen by 44.86%
$183 Corporate Governance Statement 29 Aug 2025 12:30PM $1.215 $0.670 fallen by 44.86%
$183 Appendix 4E & Annual Report 29 Aug 2025 12:28PM $1.215 $0.670 fallen by 44.86%
$183 Investor Presentation Canaccord Annual Growth Conference 15 Aug 2025 9:22AM $1.260 $0.670 fallen by 46.83%
$183 Remplir Commericalisation into $1.6B US Market Gathers Pace 13 Aug 2025 8:48AM $1.230 $0.670 fallen by 45.53%
$183 Notification regarding unquoted securities - OCC 28 Jul 2025 6:11PM $1.345 $0.670 fallen by 50.19%
$183 Option Terms and Conditions 28 Jul 2025 5:14PM $1.345 $0.670 fallen by 50.19%
$183 Proposed issue of securities - OCC 28 Jul 2025 5:12PM $1.345 $0.670 fallen by 50.19%
$183 Final Director's Interest Notice 25 Jul 2025 9:31AM $1.400 $0.670 fallen by 52.14%
$183 Proposed issue of securities - OCC 25 Jul 2025 9:30AM $1.400 $0.670 fallen by 52.14%
$183 Orthocell Announces Changes to Board of Directors 25 Jul 2025 9:04AM $1.400 $0.670 fallen by 52.14%
$183 Notification of cessation of securities - OCC 14 Jul 2025 8:29AM $1.265 $0.670 fallen by 47.04%
$183 Cleansing Notice 10 Jul 2025 4:20PM $1.240 $0.670 fallen by 45.97%
$183 Application for quotation of securities - OCC 10 Jul 2025 4:18PM $1.240 $0.670 fallen by 45.97%
$183 Orthocell Announces First US Remplir Sales Revenue 10 Jul 2025 9:03AM $1.220 $0.670 fallen by 45.08%
$183 Quarterly Activity Report & Appendix 4C 9 Jul 2025 9:00AM $1.225 $0.670 fallen by 45.31%
$183 Remplir US Rollout & 1st Surgery Investor Update 2 Jul 2025 12:46PM $1.275 $0.670 fallen by 47.45%
$183 Orthocell Bolsters Leadership with Key Hires 2 Jul 2025 9:03AM $1.255 $0.670 fallen by 46.61%
$183 Record Revenue of $2.73m in June 25 Quarter up 22.8% QoQ 1 Jul 2025 9:03AM $1.175 $0.670 fallen by 42.98%
$183 Investor Webinar 27 Jun 2025 9:50AM $1.210 $0.670 fallen by 44.63%
$183 First Surgical Use of Remplir in US$1.6 Billion US Market 27 Jun 2025 9:01AM $1.210 $0.670 fallen by 44.63%
$183 Compelling Data Highlights Remplir Competitive Advantage 19 Jun 2025 8:59AM $1.200 $0.670 fallen by 44.17%
$183 Cleansing Notice 10 Jun 2025 4:48PM $1.260 $0.670 fallen by 46.83%
$183 Application for quotation of securities - OCC 10 Jun 2025 4:45PM $1.260 $0.670 fallen by 46.83%
$183 Remplir Approved to Commence Sales in the Hong Kong Market 12 May 2025 8:56AM $1.380 $0.670 fallen by 51.45%

101 - 125 of 772 results

Page 5 of 31

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.